Stock JNJ JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Financials Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
146.1 USD -0.46% Intraday chart for Johnson & Johnson -1.20% -6.76%
Apr. 26 Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment MT
Apr. 25 Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 383,911 414,310 450,358 461,849 377,317 352,166 - -
Enterprise Value (EV) 1 392,320 424,391 452,501 477,989 383,722 345,169 331,091 319,841
P/E ratio 25.9 x 28.6 x 21.9 x 26.2 x 11.4 x 16.2 x 15.4 x 14.5 x
Yield 2.57% 2.53% 2.45% 2.52% 3% 3.3% 3.45% 3.6%
Capitalization / Revenue 4.68 x 5.02 x 4.8 x 4.86 x 4.43 x 3.98 x 3.88 x 3.75 x
EV / Revenue 4.78 x 5.14 x 4.83 x 5.03 x 4.51 x 3.9 x 3.64 x 3.4 x
EV / EBITDA 14 x 15.6 x 12.4 x 14.6 x 12.6 x 10.7 x 10 x 9.19 x
EV / FCF 19.7 x 21 x 22.9 x 27.8 x 21 x 14.9 x 14.4 x 13.5 x
FCF Yield 5.08% 4.76% 4.37% 3.6% 4.76% 6.72% 6.94% 7.42%
Price to Book 6.46 x 9.53 x 6.08 x 6.13 x 5.84 x 4.64 x 4.2 x 3.79 x
Nbr of stocks (in thousands) 2,631,872 2,632,543 2,632,597 2,614,484 2,407,279 2,409,783 - -
Reference price 2 145.9 157.4 171.1 176.6 156.7 146.1 146.1 146.1
Announcement Date 1/22/20 1/26/21 1/25/22 1/24/23 1/23/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 82,059 82,584 93,775 94,943 85,159 88,394 90,869 93,952
EBITDA 1 27,979 27,145 36,634 32,630 30,414 32,174 33,093 34,797
EBIT 1 25,593 24,574 29,244 29,965 27,460 29,004 29,957 31,241
Operating Margin 31.19% 29.76% 31.19% 31.56% 32.25% 32.81% 32.97% 33.25%
Earnings before Tax (EBT) 1 17,328 16,497 22,776 21,725 15,062 25,176 24,635 24,250
Net income 1 15,119 14,714 20,878 17,941 35,153 22,025 22,970 24,306
Net margin 18.42% 17.82% 22.26% 18.9% 41.28% 24.92% 25.28% 25.87%
EPS 2 5.630 5.510 7.810 6.730 13.72 9.001 9.513 10.08
Free Cash Flow 1 19,918 20,189 19,758 17,185 18,248 23,201 22,965 23,729
FCF margin 24.27% 24.45% 21.07% 18.1% 21.43% 26.25% 25.27% 25.26%
FCF Conversion (EBITDA) 71.19% 74.37% 53.93% 52.67% 60% 72.11% 69.39% 68.19%
FCF Conversion (Net income) 131.74% 137.21% 94.64% 95.79% 51.91% 105.34% 99.98% 97.63%
Dividend per Share 2 3.750 3.980 4.190 4.450 4.700 4.824 5.038 5.266
Announcement Date 1/22/20 1/26/21 1/25/22 1/24/23 1/23/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 23,338 24,804 23,426 24,020 23,791 23,706 24,746 25,530 21,351 21,395 21,383 22,339 22,212 22,432 21,865
EBITDA 1 9,639 7,939 9,305 9,011 9,299 7,804 8,880 8,912 8,071 6,333 7,747 8,389 8,275 7,692 8,208
EBIT 1 7,825 6,096 7,536 7,267 7,614 7,093 8,204 8,189 7,374 5,638 7,236 7,417 7,402 6,915 7,451
Operating Margin 33.53% 24.58% 32.17% 30.25% 32% 29.92% 33.15% 32.08% 34.54% 26.35% 33.84% 33.2% 33.32% 30.83% 34.08%
Earnings before Tax (EBT) 1 - 4,836 5,862 5,840 5,822 4,201 -737 6,762 5,217 4,826 6,440 6,710 6,358 5,878 -
Net income 1 3,667 4,736 - - 4,458 3,520 -68 5,144 26,028 4,049 5,354 5,446 5,200 7,348 5,471
Net margin 15.71% 19.09% - - 18.74% 14.85% -0.27% 20.15% 121.91% 18.92% 25.04% 24.38% 23.41% 32.76% 25.02%
EPS 2 1.370 1.770 1.930 1.800 1.680 1.330 -0.0300 1.960 10.21 1.670 2.200 2.202 2.212 2.710 2.294
Dividend per Share 2 1.060 1.060 1.060 1.130 1.130 1.130 1.130 1.190 1.190 1.190 1.192 1.225 1.205 1.225 1.221
Announcement Date 10/19/21 1/25/22 4/19/22 7/19/22 10/18/22 1/24/23 4/18/23 7/20/23 10/17/23 1/23/24 4/16/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 8,409 10,081 2,143 16,140 6,405 - - -
Net Cash position 1 - - - - - 6,997 21,075 32,324
Leverage (Debt/EBITDA) 0.3005 x 0.3714 x 0.0585 x 0.4946 x 0.2106 x - - -
Free Cash Flow 1 19,918 20,189 19,758 17,185 18,248 23,201 22,965 23,729
ROE (net income / shareholders' equity) 39.1% 34.9% 38.2% 23.8% 34.9% 35.2% 33.1% 31.5%
ROA (Net income/ Total Assets) 15% 12.9% 14.7% 9.71% 14.3% 13.9% 14% 14.3%
Assets 1 100,753 114,174 142,233 184,698 245,525 158,336 164,275 170,524
Book Value Per Share 2 22.60 16.50 28.20 28.80 26.90 31.50 34.80 38.60
Cash Flow per Share 2 8.720 8.810 8.750 7.960 8.900 11.10 11.10 13.40
Capex 1 3,498 3,347 3,652 4,009 4,543 4,012 4,031 4,122
Capex / Sales 4.26% 4.05% 3.89% 4.22% 5.33% 4.54% 4.44% 4.39%
Announcement Date 1/22/20 1/26/21 1/25/22 1/24/23 1/23/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Johnson & Johnson

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
146.1 USD
Average target price
173.6 USD
Spread / Average Target
+18.79%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
PFIZER, INC. Stock Pfizer, Inc.
-11.77% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. Financials Johnson & Johnson